Memorial Sloan Kettering Cancer Center

MabVax has exclusive rights to blood samples from patients vaccinated against their cancers for use as our biological source for the discovery of fully human antibodies against certain solid tumor cancers. We also have exclusive license to eight different cancer vaccines from Memorial Sloan Kettering Cancer Center. Our initial collaboration was with Philip Livingston, MD who was the head of Tumor Vaccinology at MSK. We also collaborate with Jason Lewis, Ph.D. who is Vice Chair for Research and Chief of the Radiochemistry & Imaging Sciences Service in Memorial Sloan Kettering’s Department of Radiology, and Director of Memorial Sloan Kettering’s Radiochemistry and Molecular Imaging Probe Core Facility. The Lewis lab has played an integral role in the development of MVT-2163, the PET imaging product currently in the clinic, as well as MVT-1075, the radioimmunotherapy product for which we will file an IND in 2016.

MabVax is collaborating with Eileen O’Reilly, MD, Associate Director for Clinical Research at MSK’s David M. Rubenstein Center for Pancreatic Cancer Research, who is serving as the lead investigator at the investigational site for our MVT-5873 therapeutic antibody in a Phase I clinical trial. We are also working with Christian Lohrman, MD, a diagnostic radiologist and nuclear medicine physician at MSK who is the lead investigator of our MVT-2163 PET imaging product Phase I clinical trial.  

Heidelberg Pharma

We are collaborating with Heidelberg Pharma to test an antibody drug conjugate (ADC) using our HuMab 5B1 antibody and Heidelberg’s linker and toxin technology in animal models of pancreatic cancer. Results from in vitro and in vivo experiments provide strong support for moving the program forward into further preclinical and eventually clinical development.

Rockefeller University

MabVax and The Rockefeller University’s Laboratory of Molecular Genetics and Immunology have entered into a research collaboration agreement to explore the mechanism of action of constant region (Fc) variants of the HuMab 5B1 in the role of tumor clearance. The objective is to optimize Fc receptor mediated antibody function and potentially develop a next generation HuMab-5B1 based therapeutic agent. The work will be conducted in the Laboratory of Molecular Genetics and Immunology at The Rockefeller University, which is headed by Jeffery Ravetch, M.D., Ph.D. Dr. Ravetch is a leading researcher who unraveled the importance of the antibody constant region (Fc) and described the mechanisms of antibody-mediated effector responses. The Fc portion of an antibody plays a critical functional role by binding to various cellular receptors as well as complement proteins, and it is responsible for recruiting other immune system cells to attack the tumor cell resulting in destruction of the targeted cell.